Efficacy and Safety of Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients

Sponsor
Dow University of Health Sciences
Study ID
NCT06593197
Phase
PHASE4
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apremilast with NB-UVB — COMBINATION_PRODUCT
    Tab Apremilast 30 mg twice a day with NBUVB twice per week for 8 months
  • NB-UVB — DEVICE
    NBUVB only will be given twice per week for 8 months

Study Details

Patients of non-segmental vitiligo, fulfilling the inclusion criteria will be selected from the OPD, dermatology department. It\'s an interventional study where Group A patient will be given NBUVB and Tab Apremilast 30 mg twice a day and Group B will receive NBUVB alone.

Key Dates

First listed
Sep 19, 2024
Start date
Jan 1, 2025
Status verified
Jan 2025
Primary completion
Dec 30, 2026
Completion
Mar 30, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apremilast with phototherapy
  • Active Comparator: Phototherapy alone

Primary Outcome Measure

To determine the frequency of patients halted their progression and extent of repigmentation [ Time Frame: 32 weeks ]

Related Studies